In Development for Acute and Preventive Treatment of Migraine
BHV-3500, the second product candidate in our CGRP platform, is a highly soluble small molecule CGRP receptor antagonist. It is also structurally distinct from rimegepant. The chemical properties of BHV-3500 make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration. It is initially in development as an intranasal formulation for the acute treatment of migraine. Preliminary proof-of-concept has been observed in a preclinical marmoset assay with oral delivery, and no cardiovascular safety or systemic toxicity issues have been observed in preclinical testing. We intend to submit an investigational new drug application (IND) for BHV-3500 and initiate a Phase 1 clinical trial in the second half of 2018.